Josep M. Campistol
Josep M. Campistol
MD
Verified email at clinic.ub.es
Title
Cited by
Cited by
Year
Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine1, 2
CG Groth, L Bńckman, JM Morales, R Calne, H Kreis, P Lang, JL Touraine, ...
Transplantation 67 (7), 1036-1042, 1999
10121999
SIROLIMUS IN ASSOCIATION WITH MYCOPHENOLATE MOFETIL INDUCTION FOR THE PREVENTION OF ACUTE GRAFT REJECTION IN RENAL ALLOGRAFT RECIPIENTS12
H Kreis, JM Cisterne, W Land, L Wramner, JP Squifflet, D Abramowicz, ...
Transplantation 69 (7), 1252-1260, 2000
6492000
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial
FP Schena, MD Pascoe, J Alberu, M del Carmen Rial, R Oberbauer, ...
Transplantation 87 (2), 233-242, 2009
5702009
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus
F Vincenti, S Friman, E Scheuermann, L Rostaing, T Jenssen, ...
American Journal of Transplantation 7 (6), 1506-1514, 2007
5532007
High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients
F Maduell, F Moreso, M Pons, R Ramos, J Mora-MaciÓ, J Carreras, ...
Journal of the American Society of Nephrology 24 (3), 487-497, 2013
5422013
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation
JM Campistol, J Eris, R Oberbauer, P Friend, B Hutchison, JM Morales, ...
Journal of the American Society of Nephrology 17 (2), 581-589, 2006
5262006
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial
T Coelho, LF Maia, AM da Silva, MW Cruz, V PlantÚ-Bordeneuve, ...
Neurology 79 (8), 785-792, 2012
5252012
Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis
D Adams, A Gonzalez-Duarte, WD O’Riordan, CC Yang, M Ueda, ...
New England Journal of Medicine 379 (1), 11-21, 2018
4852018
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
K Suzuki, Y Tsunekawa, R Hernandez-Benitez, J Wu, J Zhu, EJ Kim, ...
Nature 540 (7631), 144-149, 2016
4672016
Sirolimus and secondary skin-cancer prevention in kidney transplantation
S Euvrard, E Morelon, L Rostaing, E Goffin, A Brocard, I Tromme, ...
New England Journal of Medicine 367 (4), 329-339, 2012
4552012
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT‐EXT study)
A Durrbach, JM Pestana, T Pearson, F Vincenti, VD Garcia, J Campistol, ...
American Journal of Transplantation 10 (3), 547-557, 2010
4532010
Immunosuppressive therapy and malignancy in organ transplant recipients
A Gutierrez-Dalmau, JM Campistol
Drugs 67 (8), 1167-1198, 2007
3322007
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi’s sarcoma12
JM Campistol, A Gutierrez-Dalmau, JV Torregrosa
Transplantation 77 (5), 760-762, 2004
3202004
Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction
F Diekmann, K Budde, F Oppenheimer, L Fritsche, HH Neumayer, ...
American Journal of Transplantation 4 (11), 1869-1875, 2004
2902004
Inotersen treatment for patients with hereditary transthyretin amyloidosis
MD Benson, M Waddington-Cruz, JL Berk, M Polydefkis, PJ Dyck, ...
New England Journal of Medicine 379 (1), 22-31, 2018
2892018
Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal
H Kreis, R Oberbauer, JM Campistol, T Mathew, P Daloze, FP Schena, ...
Journal of the American Society of Nephrology 15 (3), 809-817, 2004
2822004
Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation
R Oberbauer, G Segoloni, JM Campistol, H Kreis, A Mota, J Lawen, ...
Transplant International 18 (1), 22-28, 2005
2552005
Interspecies chimerism with mammalian pluripotent stem cells
J Wu, A Platero-Luengo, M Sakurai, A Sugawara, MA Gil, T Yamauchi, ...
Cell 168 (3), 473-486. e15, 2017
2442017
Transforming Growth Factor-β1 Gene Polymorphisms Are Associated with Disease Progression in Idiopathic Pulmonary Fibrosis
A Xaubet, A Marin-Arguedas, S Lario, J Ancochea, F Morell, ...
American journal of respiratory and critical care medicine 168 (4), 431-435, 2003
2372003
In vivo amelioration of age-associated hallmarks by partial reprogramming
A Ocampo, P Reddy, P Martinez-Redondo, A Platero-Luengo, F Hatanaka, ...
Cell 167 (7), 1719-1733. e12, 2016
2362016
The system can't perform the operation now. Try again later.
Articles 1–20